Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2025; 31(40): 112312
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.112312
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.112312
Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy
Vasily Isakov, Alexei Goncharov, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia
Author contributions: Isakov V designed the overall concept and outline of the manuscript; Goncharov A contributed to the discussion of the manuscript; Isakov V and Goncharov A contributed to the writing and editing the manuscript, and review of literature.
Supported by Ministry of Science and Higher Education of the Russian Federation, No. FGMF-2025-0003.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoe Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com
Received: July 23, 2025
Revised: August 25, 2025
Accepted: September 30, 2025
Published online: October 28, 2025
Processing time: 96 Days and 15.4 Hours
Revised: August 25, 2025
Accepted: September 30, 2025
Published online: October 28, 2025
Processing time: 96 Days and 15.4 Hours
Core Tip
Core Tip: This editorial highlights a pivotal multicenter randomized controlled trial from China demonstrating that vonoprazan (VPZ)-based triple therapy achieves superior or non-inferior Helicobacter pylori eradication rates compared to standard bismuth quadruple regimens, even in high clarithromycin resistance regions. The 10-day VPZ-amoxicillin-clarithromycin regimen exceeded 90% per-protocol efficacy with fewer adverse events, offering a simplified, well-tolerated alternative aligned with global treatment goals. These findings underscore a shift in empirical first-line therapy and support the integration of VPZ into updated regional and international guidelines.